enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.